viii

Related by string. VIII * * Dragon Quest VIII . Mitsubishi Lancer Evo VIII . Henry VIII . King Henry VIII . Uga VIII . viii insufficient . viii inability . mascot Uga VIII . UGA VIII . introduce Uga VIII . King Edward VIII . factor VIII . Class VIII . Edward VIII . Region VIII . Factor VIII . Article VIII . Phase VIII . NELP VIII . Final Fantasy VIII . VIII LP . Title VIII . Std VIII . VIII IX *

Related by context. All words. (Click for frequent words.) 82 vii 74 ix 74 xii 73 xiii 73 iv 72 xv 72 xiv 72 xviii 71 xvi 70 iii 70 xxi 69 xxii 69 xvii 69 xix 67 xi 65 vi 65 Immtech clinical trials 64 ii 63 xxiii 63 xxiv 62 xxv 62 xxvi 59 xxvii 58 ourability 57 xxviii 56 substantial indebtedness 55 risksassociated 55 rapid technological 55 without limitation 54 risks associatedwith 54 governmental approvals 54 regarding Heska 54 successfully integrate 53 requirements xxii 53 Pure Biofuels ability 53 materially adversely affect 52 general economicconditions 52 DSL.net s 52 Immtech scientists 51 incur unanticipated 51 unanticipated difficulties 51 xxxii 51 tenant bankruptcies 51 adversely affect 51 market PolyHeme commercially 51 multiple lease terminations 51 otherfactors 51 collect reinsurance recoverables 51 theability 50 withrespect 50 incurrence 50 economicconditions 50 legal proceedings xxi 50 impactof 50 party VLSI fabrication 50 contingent guaranties 50 obtaining regulatory approvals 49 statementsregarding 49 materially adversely affected 49 SeraCare competitors 49 technological obsolescence 49 xxxiii 49 pricing pressures 49 Unitholder liability 49 HealthGate ability 49 inventory obsolescence 49 affecting Amarin 49 changesin 48 HANA MAX 48 relatedto 48 prepayment speeds loan originations 48 Thalomid R 48 permitting timelines 48 ability tosuccessfully 48 affecting mortality morbidity 48 Heska reliance 48 related thereto 48 consummating acquisitions 48 notlimited 48 PharMerica LTC Transaction 48 ARLP Partnership 48 results ofoperations 48 deploy MDCE services 48 heading RISK FACTORS 48 adversely affecting Cubist 48 lender consents 48 thereby negatively impacting 48 retrocessional coverage 48 arenot limited 47 suchforward looking 47 orotherwise 47 otherrisks 47 EMPOWER pivotal trial 47 without limitation Terremark 47 relating 47 anduncertainties 47 unanticipated 47 risks anduncertainties 47 adversely affect Waste Connections 47 market fluctuations investee 47 orother 47 nonoccurrence 47 ourproducts 47 Bioaccelerate compounds under 47 causeactual results 47 vii viii 47 fluctuations 46 differ materially 46 SumTotal Systems filings 46 FierceGovernmentIT tracks 46 uncertainties 46 risksand uncertainties 46 vii IBC 46 Item IA 46 risks associated 46 marketconditions 46 d Reflects 46 filingswith 46 SANCTURA SANCTURA XR VANTAS 46 Crisa acquisition 46 periodic redeterminations 46 including withoutlimitation 46 vi vii 46 PD2i Analyzer ™ 46 BioSante licensees 46 Projects Initiation 46 Invitel Holdings operates 46 xi unanticipated 46 adverse 46 VIOXX Lawsuits 46 associated therewith 46 acquisitions dispositions 46 associatedwith 46 uncollectability 46 adversely affecting 45 representations warranties covenants 45 couldcause 45 withoutlimitation 45 TranSwitch indebtedness 45 expenses associated therewith 45 uncertaintiesthat 45 refinance indebtedness 45 xvi beer 45 communicate differentiations effectively 45 unfavorable geologic 45 unitholder liability 45 aresubject 45 Shire plc Attention Deficit 45 Lenfest ii 45 xv licensing 45 affirmative covenants 45 CAUTION ANY ATTEMPT 45 Equinix filings 45 Protonix ® 45 Atheros Quarterly Report 45 work stoppages slowdowns 45 gastrointestinal GVHD include 45 Sepracor anticipates 45 unanticipated geological 45 ofsuch 45 xxix 45 manufacture PolyHeme 45 Somaxon ability 45 successfully commercialize 45 areforward looking 45 Bioenvision dependence 45 DARA intellectual property 45 borrower depositor 45 thereunder 45 BiDil XR drug 45 successfully integrate Legerity 45 Form 8K #K 44 d Represents 44 renegotiation nullification 44 limitedto 44 adverse determinations 44 Risks uncertainties 44 MTI MTI Micro 44 commercialize ZYFLO CR 44 product introductions 44 LPM TM 44 Erythropoietic therapies may 44 ADSI reliance 44 Mago ® 44 SANCTURA SANCTURA XR NEBIDO 44 postretirement benefit obligations 44 OSI Pharmaceuticals filings 44 securityholder approvals 44 xiv licensing 44 i# implanters 44 HF Lenfest member 44 work stoppages quarantines 44 PLAVIX R patent 44 affecting IsoTis 44 Prelude SkinPrep Systems 44 vii Dynamic 44 successfully commercialize Silenor 44 Company noncontributory defined 44 differmaterially 44 regardingthe 44 constitutes discloseable transaction 44 CDO financings 44 PGP Acquisition 44 futureresults 44 InnSuites Hotels 44 Atheros Annual Report 44 Cerro Negro concession 44 vii Cubist ability 44 especially Copaxone ® 44 party payors 44 [013] 44 ceded reinsurance 44 affecting Pennichuck Corporation 44 Fampridine SR Acorda Therapeutics 44 involverisks 44 FalconStor OEM 43 tarmac strandings Hanni 43 differ materiallyfrom 43 Candente relies upon 43 incorporate proprietary Microvolt 43 dispositions financings 43 c Relates 43 incorporating FalconStor 43 delinquencies defaults 43 REIT xi 43 heading ITEM 1A 43 iii Cubist 43 DIP Loan 43 Acorda Therapeutics intellectual property 43 AspenTech periodic reports 43 § #-#-# b [003] 43 liabilities slippage 43 INTEGRILIN R eptifibatide Injection 43 Secure Computing periodic 43 carryforwards 43 ii Immtech ability 43 mergers consolidations 43 Enpath ability 43 Textainer expectation 43 LOPROX R 43 SURETY LICENSES c 43 Alnylam dependence 43 risks unanticipated reclamation 43 Nortel strategic alliances 43 collaborations Pharmacopeia 43 indebtedness covenant 43 § #.#-# [007] 43 technological innovations adversely affecting 43 TranSwitch filings 43 postretirement benefit plans 43 consolidations restructurings bankruptcies 43 reinsurance recoverables owed 43 competitively procured pursuant 43 tomaintain 43 risks associated therewith 43 productsand services 43 PolyHeme successfully 43 theCompany 43 Market Disruption 43 JLG acquisition 43 Iusacell Celular 43 #.#-# b [001] 43 iii iv 43 NxStage anticipates 43 prices drydocking 42 regulatory approvals 42 CORLUX CORT # 42 brine inflows 42 xiv unanticipated 42 render PolyHeme obsolete 42 Puricase PEG uricase 42 TP# CETi 1 42 theSecurities 42 date xvii Conversion 42 Johnell O 42 manufacture RISPERDAL CONSTA 42 maycause 42 cause actual 42 PLIVA acquisition 42 principally attributable 42 materially differ 42 SUPPRELIN LA DELATESTRYL 42 PC OEMS 42 non capitalizable 42 VYVANSE TM lisdexamfetamine 42 collectibility 42 integrate CyVera technology 42 Bioenvision filings 42 obsolete inventory 42 Partially offsetting these 42 materially impair 42 Black Canyon mica 42 couldcause actual results 42 Esterhazy Saskatchewan potash 42 CholeraGarde R Peru 42 Form #KSB filed 42 Carrier Ethernet www.soapstonenetworks.com 42 P. #a 42 SANCTURA R 42 USC § #f 42 APDN SEC 42 ADA CS 42 actualresults 42 indemnification obligations 42 primarily attributable 42 recompetes 42 Auxilium anticipates 42 #.#-# b [002] 42 maycause actual results 42 Entereg TM 42 dimesylate Attention Deficit 42 competing steel minimills 42 toreflect 42 requisite stockholder 42 Shire Attention Deficit 42 uncertainties materialize Shire 42 includingstatements regarding 42 Gastroesophageal Reflux 42 deCODE filings 42 BY AN ENTRANT 42 ENABLE Phase 2 42 Biogold Fuels 42 Jupiterimages respective 42 cadence regulatory approvals 42 #,#,# #,#,# -DH Ellis Burks 42 current physiologic opioid 42 Accurel 42 differ materially fromthose 42 postretirement benefit 42 retrocessional reinsurance 42 intellectualproperty 42 Kyowa Kirin 42 payer reimbursement 42 EHSK 42 diminishing quantities 42 Nortel Networks strategic alliances 42 uncollectible accounts receivable 41 Omtool periodic reports 41 andmarket 41 TrueKnowledge Platform TM 41 Variable annuities involve 41 Kronos TiO2 41 OraTest R 41 maydiffer materially 41 Slightly offsetting 41 Rexahn actual 41 cancellations rescheduling 41 Bioenvision compounds under 41 Daytrana TM 41 Neurokine 41 DTR #.#.# b 41 BOPET film industry 41 candidate Ramoplanin 41 e# periodic 41 Gottschalks Annual Report 41 Operations contained therein 41 thereto 41 Offerors Commercial applies 41 Priszm LP 41 capture exosomes 41 PepsiCo bottling 41 Excluding acquisitions divestitures 41 MHG Annual Report 41 Questcor intellectual property 41 natural disasters epidemics 41 party payor reimbursement 41 i# implanter 41 CAUTIONARY STATEMENT Statements 41 - Net [002] 41 Becancour facilities 41 adversely impact 41 Factors influencing 41 COPL 41 VimpelCom disclaims 41 bone marrow fibrosis 41 enforce MOSAID 41 payor acceptance 41 OMNI dependence 41 TriPath Oncology 41 risks uncertainties 41 excludes depreciation amortization 41 TRISENOX R 41 andgeneral 41 involve risksand uncertainties 41 Transeastern JV 41 andeconomic 41 DIP Facility 41 Financing Condition 41 Liquor Stores LP 41 Compans 41 VeraTag assays 41 changes Decorize dependence 41 Second Supplemental Indenture 41 negatively impact 41 Rexahn licensees 41 persistency mortality 41 theforward looking 41 ultimate recoverability 41 Colo. Sess 41 torsemide ER 41 noticeably thinner stark 41 CompanyaEUR TM s 41 andoperating 41 x Immtech 41 Exelbine 41 visit http:/www.nationwide.com 41 transactions contemplated 41 credit carryforwards 41 #,# -SPIN BOLDAK Afghanistan 41 § #.#-# [004] 41 andfinancial 41 accounting pronouncements 41 adversely affect Hologic 41 anyforward looking 41 Optimer filings 41 adversely affect Linktone 41 AudioCodes filings 41 Tronox Annual Report 41 SemGroup LP SemGroup 41 MOSAID litigation 41 OPAXIO pixantrone 41 molecular immunohematology products 41 Phyto Source LP 41 Idenix anticipates 41 transportation storage terminalling 41 inaccurately estimating 41 Insolvency Proceedings 41 Acapodene R 41 Mediaseed R 41 Cautionary Disclosures 41 excimer laser atherectomy 41 BioGlue ® 41 MicroTel 41 § #-#-# [005] 41 Fampridine SR delays 41 Avivo Corporation 41 SiriCOMM periodic reports 41 MorAmerica Capital 41 SILENOR ™ 41 Sunesis clinical trials 41 EcaFlo TM 41 SOLODYN R 41 uncertainties materialize Shire plc 41 GEROVA underwrites insurance 41 difficulties foreseeing 41 expropriation nationalization 41 PDI periodic filings 41 prepayment speeds loan 41 XVII inability 41 mortality persistency 41 acquisitions divestitures restructurings 41 strategic alliances seasonality 41 calcium hypochlorite markets 41 subjectto 40 currency fluctuations imprecision 40 PD2i Cardiac Analyzer 40 opioid bowel dysfunction 40 XP# XP# 40 #.# subd [003] 40 ad valorem taxing 40 punitive incidental 40 Partially offsetting 40 SearchHelp communications 40 debt extinguishments 40 PVR lessees 40 collaborations Pharmacopeia anticipated 40 #,#,# #,#,# -LAS VEGAS MGM Resorts 40 5 lipoxygenase inhibitor 40 CFR #.#b 40 timing rescheduling 40 distinguishing MDCE products 40 newproducts 40 SIMOX SOI 40 sublicensees 40 Subordinate MBS 40 f h 40 Congoleum undertakes 40 i #.# subds 40 Dimension BST 40 Receivable purchasing 40 theavailability 40 adversely affect NextEra Energy 40 NNL failure 40 molecular immunohematology 40 positive inotropic agents 40 Filtran Microcircuits Inc. 40 Healive TM 40 BlackPearl Announces 40 website www.gladiatorstocks.com 40 xxxi 40 CompAir acquisition 40 may diverge numerically 40 AngelCiti expectations 40 KRYSTEXXA TM 40 Factors Affecting Future 40 Somewhat mitigating 40 contingently liable 40 -#,# -#,# -#,# -#,# [003] 40 forward lookinginformation 40 andother 40 Company nanocrystalline materials 40 dispositions 40 Goggin holed 40 cyclical downturns affecting 40 PD2i ® algorithm 40 theseforward looking 40 resultof 40 Rosetta dependence 40 proprietary Capillary Aerosolization Technology 40 CCR5 inhibitors entry 40 - Effect [003] 40 OTC ZEGERID 40 DECREASE IN CASH AND 40 APTIMA HPV assay 40 arebased 40 consummation 40 Gaoan facility 40 These statementsare 40 acquisitions divestitures joint ventures 40 love veronica Mars 40 impair Lillian Vernon 40 dispositions joint ventures 40 LAE reserves 40 InfoSearch filings 40 ofany 40 unconsolidated investments 40 Subscription Fulfillment Services 40 Baqoubah north 40 Refinancing Transactions 40 inherent uncertainty 40 EPIXTAR 'S 40 vendor unseasonable weather 40 JM Dutton adds 40 EAHA shall automatically 40 GoFish periodic filings 40 tosuccessfully 40 b Relates 40 PD2i Analyzer 40 b Represents 40 successfully commercialize Iluvien 40 Defendants misrepresented 40 consents authorizations 40 Terremark filings 40 INTEGRILIN ® 40 product discontinuances 40 VIACOM INC. AND SUBSIDIARIES 40 NeoPharm anticipates 40 cardiorespiratory diagnostic products 40 - Effect [009] 40 Partially offset 40 Lordsburg Mining District 40 Partnered Brands segment 40 anticipated drydocking 40 - Total [037] 40 outstanding indebtedness 40 Regulation XXX 40 Favrille filings 40 economically recoverable coal 40 exposes InterMune 40 intercompany indebtedness 40 looking statements.These 40 Cinryze TM 40 c Reflects 40 Ascendiant 40 retail industries repositionings 40 integrate restructurings consolidations 40 reinsurance recoverables 40 Zemiva ™ 40 VELCADE therapy 40 excluding drydocking 40 CyberDefender expectation 40 biotherapeutic drugs 40 #,#,# Deferred [001] 40 TILC 40 - - Net [013] 40 refund guarantors 40 Orrstown Financial conducts 40 Lasertel subsidiary 40 FINANCIAL CONDITION AND 40 suchstatements 40 valuation allowances 40 AcryMed Incorporated 40 SIFT Rules 40 regarding Anviron 40 innovative StarCured ® 40 Varvarinskoye Project 40 x fluctuating beryllium 40 FSAH 40 DJO Merger 40 OREO valuation 40 n h r 40 TRIOLEX HE# APOPTONE HE# 40 Absentee bids shall 40 servicemark risks xiv 40 TeamStaff filings 40 c html plugins 40 materially different 40 involve risks anduncertainties 40 - -Billeaudeau 40 Chase Kishner 40 fluctuations cyclicality 40 Cytogen dependence 40 requisite regulatory approvals 40 iii Immtech ability 40 Company 40 forward lookingstatements 40 depreciation depletion amortization 40 Hyperparathyroidism 40 Restated Revolving Credit 40 eTag assays 39 Carnoustie Turnberry Royal Troon 39 xxvi introduction 39 AMPS Risk 39 OTHER INCOME EXPENSES 39 reinsurance recoverable 39 mergers dispositions 39 periodic reports 39 Consists primarily 39 commercialize technological innovations 39 Web site http:/www.EmergingStockReport.com 39 Oxandrin ® 39 Actual results 39 themanagement 39 - Net [017] 39 ELESTAT intellectual property 39 Zi OEM 39 VIOXX Product 39 supplemental indenture effecting 39 t h r 39 embolic coiling 39 concerning Alexza 39 Modifiable risk 39 breast tenderness bloating 39 MAb therapy 39 Disruptions uncertainty 39 forwarda ^ looking 39 intercompany arrangements 39 geology continuity 39 assorted pigments resins 39 looking statements 39 Merger Transactions 39 Somewhat offsetting 39 IoGen ™ 39 xviii currency 39 arising 39 Colihues tailings impoundment 39 c Consists 39 unfavorable prognostic 39 - OperAyscough 39 RR Donnelley periodic filings 39 SonoPrep device 39 Hengdali facility 39 Agreement constitutes discloseable 39 Proposed Arrangement 39 novel proprietary KL4 39 stockholder approvals 39 charterhire rates 39 Backs Gio Aplon 39 bioresearch monitoring 39 Form# K 39 Hejia Software 39 Zemiva TM Trofex TM 39 Reports Inducement Grants 39 Wikifamilies 39 website www.FreePennyAlerts.com 39 asset impairments 39 Hengdali 39 early extinguishments 39 pharmacogenomic tests 39 favoring downsizing deinstitutionalization 39 Theseforward looking 39 serious cardiovascular thrombotic 39 Entrust periodic 39 eHealth ecommerce 39 satisfy indemnification obligations 39 histrelin manufacturing marketing 39 Comarco Announces 39 affecting O2Micro 39 commercializing ArteFill 39 OneBeacon filings 39 surety bonding increased 39 inIsrael 39 CEFF financings subject 39 contingent liabilities 39 NeuroMove TM 39 inflationary pressures adversely affecting 39 website www.PennyStockAlley.com 39 customers licensees licensors 39 -Tilak Marg 39 concerning Epigenomics AG 39 Multiemployer Pension Plan 39 i g 39 Repl. 39 SEC Rule #g# 39 reserve estimations 39 capitated contracts 39 b Excludes 39 CHDT SEC Filings 39 XL# anticancer compounds 39 table summarizes 39 Risk Factors 39 ecommerce marketplaces 39 franchisees licensees 39 Kinsevere copper mine 39 offuture 39 leaseback transactions 39 GrowthWorks refers 39 #,# -INDUSTRIES INC. 39 Vanda inability 39 collectability 39 Chaim Lebovits President 39 Purchased intangibles 39 MSCRAMM 39 xii trademark 39 Analyte Specific Reagent 39 satellite datacasting market 39 pricing IMPAX 39 NOL utilization 39 Tekmira disclaims any 39 NOLs 39 depreciation accretion 39 activate telomerase 39 AcryMed technologies 39 CLX Investments 39 Retrograde ejaculation 39 USED IN FINANCING ACTIVITIES 39 Warfarin Sodium 39 EcaFlo ® equipment 39 shipyards charterers lenders 39 intellectual property infringement 39 supplemental indenture containing 39 OOK ETF 39 Sunesis nonclinical studies 39 DFAR #.#-# 39 subvented APR 39 USC § #a [002] 39 - Effect [006] 39 Risk Factors section 39 str = i 39 - Net [022] 39 EnPro Industries Announces 39 HealthTronics periodic filings 39 c Represents 39 Somewhat offsetting these 39 Earnout 39 MultiCell bases 39 FGIC insured 39 Tucows filings 39 consolidated VIEs 39 operated bakery cafe 39 MGCD# MGCD# [001] 39 materially affect 39 #,#,# Commitments 39 impacting WesBanco 39 relating thereto 39 FastFunds Financial Corporation 39 g r 39 hepatic lipid 39 No. #R Consolidation 39 commercially mineable 39 Hiru Corporation ability 39 Convertible Notes tendered 39 Lordsburg mill comprising 39 purchaserâ € ™ 39 visit www.targanta.com 39 Enhance Biotech 39 xv adverse 39 Including newbuildings 39 gathering compressing treating 39 innovative StarCured R 39 unseasonable weather patterns 39 cash fl ows 39 Detrex stock 39 xiii trademark 39 novel therapeutic modality 39 concerning AudioCodes 39 applicable regulatory approvals 39 embedded SuperFlash 39 Therein lurks 39 joint ventures strategic alliances 39 commercialize BiDil 39 -lipid nanoparticles 39 immunological tolerance 39 Consists 39 TRISENOX ® 39 Syntroleum Process 39 LinuxLink reduces 39 Kosan dependence 39 - Segment [005] 39 LOUIS Oshiomogho Atogwe 39 technology crystalline ingot 39 Inc NASDAQ CISG 39 mortality morbidity 39 evaluating Questcor 39 services visit www.networkengines.com 39 Oxandrin 39 eTelcharge.com Inc. 39 Vital Images SEC 39 Retains CCG Investor Relations 39 #,#,# [023] 39 Discontinued Operations Including 39 Liability Lawsuits 39 thereof 39 thepotential 39 franking credits attached 39 viii insufficient 39 transport cystine 39 - - [090] 39 adopting SFAS #R 39 Note Movie showtimes 38 Colin Firth portrays 38 adversely affect Univest Corporation 38 v Dot VN 38 Illumigen Biosciences Inc. 38 Publication Classified Ad 38 EHT AGN 38 minimally dilutive 38 Xechem Nigeria 38 sublicense agreements 38 Sepracor licensees 38 revise anyforward looking 38 SmarTire dependence 38 unconsolidated investees 38 indebtedness incurred 38 b Reflects 38 Prospectuses contain 38 cause actualresults 38 e mail lifestyle@readingeagle.com 38 AirIQ Announces 38 Achillion anticipates 38 Airvana anticipates 38 promulgated thereunder 38 R DYNACIN R 38 incidental thereto 38 todiffer materially 38 h g 38 customary representations warranties 38 Mitsue Pipelines 38 Historian Antonia Fraser 38 postretirement benefits 38 professionals technological obsolescence 38 Durus Life 38 Pharmos filings 38 Consummation 38 Varian Semiconductor dependence 38 - - [085] 38 vi renegotiation nullification 38 Direct xi Indirect 38 others Mannatech inability 38 liquidating Filene Basement 38 - Net [014] 38 xii Type 38 Somaxon interpretation 38 Cytokinetics specified 38 personnel xvii inability 38 - Gross ProEva DeHart 38 viii inability 38 indentures governing 38 asset dispositions 38 Synbiotics Corporation 38 - Net [012] 38 payor reimbursement 38 - Operating [019] 38 Scheduler Plus 38 theimpact 38 opioid tolerance 38 - - Net [023] 38 Oxandrin R 38 safeharbor 38 adverse publicity 38 obligations hereunder 38 PS# Pharmacopeia ability 38 hpSCs avoid ethical 38 Aeolus Pharmaceuticals Announces 38 Analysis C.1 Strengths 38 #,#,# #,#,# Deferred [002] 38 thereby impairing 38 - Loss [020] 38 Negative Outlook reflects 38 #.# subd [004] 38 disinterested Shareholder approval 38 GYN Surgical revenues 38 SEC Form #F 38 affect NYMET Holdings 38 Nortel unfunded 38 asset monetizations 38 - -Commey 38 accurately predict 38 Knoxville MSA 38 connection therewith 38 possession DIP 38 NET INCREASE IN 38 Master Commutation Release 38 itsproducts 38 EVIZON TM squalamine lactate 38 outlaws bribing 38 ™ pralatrexate injection 38 RPTN common 38 agitation hallucinations 38 multimedia duplication replication 38 affirmations reflect 38 tiny pteropod 38 Yima project 38 omecamtiv mecarbil 38 SCHIP Extension 38 within capitated agreements 38 affect Petroflow 38 factorsthat 38 While Ambrilia anticipates 38 attribution authenticity provenance 38 dependent upon 38 atherosclerotic cardiovascular 38 QSound periodic reports 38 therefrom 38 Thelin tm 38 WDEQ Permit 38 execute supplemental indenture 38 peramivir clinical trials 38 prepetition liabilities 38 Risk Factors Relating 38 - - Income [012] 38 Evidence Therapeutic study 38 - Operating Expenses [001] 38 without limitation Newlook 38 BioGold Fuels 38 NetVault TM 38 Quantitative Disclosures About 38 KNA ULC 38 RASP Data Security 38 Kanis JA 38 minerals inc 38 Telesat Telesat leverage 38 Orosi Mill project 38 indentures pursuant 38 include ClindaReach TM 38 selective GR 38 Unfavorable 38 update anyforward looking 38 WNS ADS 38 related Functional Somatic 38 Corporation PGIC 38 cause actual resultsto 38 Secondary endpoints include 38 Sepracor patents 38 - Net [010] 38 muscles abdominal distension 38 vary materially 38 results todiffer materially 38 unconsolidated investee 38 viii component 38 free E Newsletters 38 Sponsored REITs 38 Aircastle Limited filings 38 Linjeta TM 38 § #-#-#.# 38 AMETEK filings 38 please visit www.middlebrookpharma.com 38 Fundamental Freedoms ECHR 38 de novo branching 38 Proposed Financing 38 INACCURACIES 38 Sets Earnings Release 38 indemnification clauses 38 Ambrilia proceedings 38 Cytogen periodic filings 38 - Net [011] 38 Manufacturer OEM 38 UniversalPHOLED 38 joint ventures divestitures 38 - Operating [006] 38 Monovisc 38 MassARRAY platform 38 concerning Xanthus 38 riverboat cruise ship 38 - Net [007] 38 SemCanada Crude 38 R Lotrel 38 bulk amorphous alloys 38 IMPAX filings 38 maintain penile erection 38 - -champioship 38 - - Net [029] 38 ENTOCORT EC 38 visit www.bioject.com 38 thereby adversely affecting 38 uncertainties impacting Sirit 38 #,#,#,#,# [010] 38 oversubscription privilege 38 ourbusiness 38 - Effect [016] 38 Cautionary Information 38 favorably impacted 38 necessary regulatory approvals 38 joint Clairvest CEP 38 cyclicality inherent 38 acquisitions divestitures transfers 38 products visit www.adm.com 38 forecasted timelines 38 LogicVision disclaims

Back to home page